27713123|t|Abnormal amphiregulin expression correlates with gastric cancer prognosis
27713123|a|Gastric cancer (GC) is a global health issue with a high mortality rate. Early diagnosis and tracking of GC is a challenge due to a lack of reliable tools. Amphiregulin (AREG) is a member of the epidermal growth factor (EGF) family that activates growth signaling upon binding of EGF receptors. Elevated AREG expression is associated with various pathological conditions, including cancer. Here, we investigated whether increased AREG expression is a disease indicator and/or prognostic biomarker for GC. We used tissue microarray and quantitative real-time polymerase chain reaction to assess AREG expression in clinical tissue specimens at various stages of GC and a conducted bioinformatics analysis to evaluate the value of AREG over-expression as a GC biomarker. We found that both mRNA and protein expression of AREG were increased in the tissues of GC patients when compared to tissues from non-cancer patients or normal tissues. High expression of AREG was also associated with GC clinicopathological characteristics and poor survival. Thus, over-expression of AREG could serve as a novel GC biomarker, and active surveillance of its expression could be a novel approach to GC diagnosis and monitoring.
27713123	0	8	Abnormal	T033	C0205161
27713123	9	21	amphiregulin	T116,T123	C0051755
27713123	22	32	expression	T045	C1171362
27713123	33	43	correlates	T039	C0871083
27713123	49	63	gastric cancer	T191	C0699791
27713123	64	73	prognosis	T058	C0033325
27713123	74	88	Gastric cancer	T191	C0699791
27713123	90	92	GC	T191	C0699791
27713123	99	118	global health issue	T091	C1456573
27713123	131	145	mortality rate	T081	C0205848
27713123	153	162	diagnosis	T033	C0011900
27713123	179	181	GC	T191	C0699791
27713123	187	196	challenge	T058	C0805586
27713123	230	242	Amphiregulin	T116,T123	C0051755
27713123	244	248	AREG	T116,T123	C0051755
27713123	255	261	member	T098	C0680022
27713123	269	292	epidermal growth factor	T116,T121,T125	C0242275
27713123	294	297	EGF	T116,T121,T125	C0242275
27713123	311	320	activates	T043	C1514758
27713123	321	337	growth signaling	T044	C1155379
27713123	343	350	binding	T052	C1145667
27713123	354	367	EGF receptors	T116,T126,T192	C0034802
27713123	369	377	Elevated	T080	C3163633
27713123	378	382	AREG	T116,T123	C0051755
27713123	383	393	expression	T045	C1171362
27713123	397	412	associated with	T080	C0332281
27713123	421	444	pathological conditions	T046	C0030660
27713123	456	462	cancer	T191	C0006826
27713123	473	485	investigated	T169	C1292732
27713123	494	503	increased	T081	C0205217
27713123	504	508	AREG	T116,T123	C0051755
27713123	509	519	expression	T045	C1171362
27713123	525	542	disease indicator	T201	C0005516
27713123	550	570	prognostic biomarker	T080	C1514475
27713123	575	577	GC	T191	C0699791
27713123	587	604	tissue microarray	T075	C1519522
27713123	609	621	quantitative	T081	C0392762
27713123	622	657	real-time polymerase chain reaction	T063	C1709846
27713123	668	672	AREG	T116,T123	C0051755
27713123	673	683	expression	T045	C1171362
27713123	673	683	expression	T045	C1171362
27713123	696	712	tissue specimens	T024	C1292533
27713123	734	736	GC	T191	C0699791
27713123	753	767	bioinformatics	T091	C1140694
27713123	768	776	analysis	T062	C0936012
27713123	780	788	evaluate	T058	C0220825
27713123	802	806	AREG	T116,T123	C0051755
27713123	807	822	over-expression	T045	C1171362
27713123	828	830	GC	T191	C0699791
27713123	831	840	biomarker	T201	C0005516
27713123	861	865	mRNA	T114,T123	C0035696
27713123	870	888	protein expression	T045	C1171362
27713123	892	896	AREG	T116,T123	C0051755
27713123	902	911	increased	T081	C0205217
27713123	919	926	tissues	T024	C1292533
27713123	930	932	GC	T191	C0699791
27713123	933	941	patients	T101	C0030705
27713123	947	955	compared	T052	C1707455
27713123	959	966	tissues	T024	C1292533
27713123	972	991	non-cancer patients	T101	C0030705
27713123	995	1009	normal tissues	T024	C0040300
27713123	1016	1026	expression	T045	C1171362
27713123	1030	1034	AREG	T116,T123	C0051755
27713123	1044	1059	associated with	T080	C0332281
27713123	1060	1062	GC	T191	C0699791
27713123	1063	1082	clinicopathological	T046	C0030660
27713123	1083	1098	characteristics	T080	C1521970
27713123	1103	1116	poor survival	T062	C0038953
27713123	1124	1139	over-expression	T045	C1171362
27713123	1143	1147	AREG	T116,T123	C0051755
27713123	1171	1173	GC	T191	C0699791
27713123	1174	1183	biomarker	T201	C0005516
27713123	1189	1208	active surveillance	T058	C1827061
27713123	1216	1226	expression	T045	C1171362
27713123	1256	1258	GC	T191	C0699791
27713123	1259	1268	diagnosis	T033	C0011900
27713123	1273	1283	monitoring	T061	C1302396